Pharmacist intervention confers benefits on cardiovascular outcomes

27 Jun 2022
Pharmacist intervention confers benefits on cardiovascular outcomes

Pharmacist interventions help improve cardiovascular disease management, including risk factor control, better medication adherence, and reduction in morbidity and mortality, a study has found.

The researchers explored the databases of Medline, Embase, and the Cochrane Library from inception to July 2021 and identified meta-analyses of randomized controlled trials. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the quality of evidence.

A total of 9,308 publications were identified, of which 149 full-text articles were assessed for inclusion. Only 24 studies with 85 unique meta-analyses examining the effects of pharmacist intervention on cardiovascular risk factors and outcomes were included in the umbrella review.

Of the 85 unique meta-analyses, 61 (71.7 percent) reported significant impacts of pharmacist intervention. Based on the GRADE approach, 63.4 percent of meta-analyses had large heterogeneity (I2 >50 percent), whereas 1.2 percent were graded as high quality, 16.5 percent moderate, 32.9 percent low, and 49.4 percent very low.

In meta-analyses with moderate quality, pharmacist intervention led to a significant reduction in risk factors (including 6/3-mm Hg decrease in blood pressure, an increase in the rate of lipid control [pooled odds ratio (OR), 1.91, 95 percent confidence interval (CI), 1.55‒2.35], glucose control [OR, 3.11, 95 percent CI, 2.3‒4.3], and smoking cessation [OR, 2.3, 95 percent CI, 1.33‒3.97]), as well as improved adherence to medication (OR, 1.67, 95 percent CI, 1.38‒2.02).

Pharmacist interventions also resulted in a significant decrease in all-cause mortality (OR, 0.72, 95 percent CI, 0.58‒0.89) and better quality of life among patients suffering from chronic heart failure.

Editor's Recommendations